Showing results (51-60 of 70) with videos related to
Sort By:
Pageof 7
Cancer Discovery|November 14, 2024
The UBA1-STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint BlockadeYi Bao, Gabriel Cruz, Yuping Zhang, et al.Biorxiv : the Preprint Server for Biology|March 11, 2024
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerTongchen He, Caleb Cheng, Yuanyuan Qiao, et al.Cell|December 16, 2017
Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNAYasuyuki Hosono, Yashar S Niknafs, John R Prensner, et al.Biorxiv : the Preprint Server for Biology|March 11, 2024
PIKfyve controls dendritic cell function and tumor immunityJae Eun Choi, Yuanyuan Qiao, Ilona Kryczek, et al.Cell Reports. Medicine|October 1, 2024
Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibitionYu Chang, Xiaoju Wang, Jianzhang Yang, et al.Cancer Discovery|April 6, 2013
Identification of targetable FGFR gene fusions in diverse cancersYi-Mi Wu, Fengyun Su, Shanker Kalyana-Sundaram, et al.Nature Genetics|November 5, 2013
Activating ESR1 mutations in hormone-resistant metastatic breast cancerDan R Robinson, Yi-Mi Wu, Pankaj Vats, et al.Proceedings of the National Academy of Sciences of the United States of America|April 1, 2024
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerTongchen He, Caleb Cheng, Yuanyuan Qiao, et al.Nature Genetics|October 3, 2025
Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancerJie Luo, Zhixiang Chen, Yuanyuan Qiao, et al.The Journal of Clinical Investigation|September 16, 2025
CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical modelsYi Bao, Yu Chang, Jean Ching-Yi Tien, et al.Pageof 7